ES2110977T3 - Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa. - Google Patents

Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa.

Info

Publication number
ES2110977T3
ES2110977T3 ES91304487T ES91304487T ES2110977T3 ES 2110977 T3 ES2110977 T3 ES 2110977T3 ES 91304487 T ES91304487 T ES 91304487T ES 91304487 T ES91304487 T ES 91304487T ES 2110977 T3 ES2110977 T3 ES 2110977T3
Authority
ES
Spain
Prior art keywords
carbon atoms
aryl
lower alkyl
pirrolidinas
aldosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304487T
Other languages
English (en)
Inventor
Michael Sotirios Malamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2110977T3 publication Critical patent/ES2110977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I) Y A SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R ELEVADO 1 Y R (AL CUADRADO) SON INDEPENDIENTEMENTE HIDROGENO, ALQUILO QUE CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO, HALOGENO, ALCOXI INFERIOR QUE CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO, TRIFLUOROMETILO, NITRO, ARILO O ARIL (ALQUILO INFERIOR) OXI DONDE EL ARILO CONTIENE ENTRE 6 Y 10 ATOMOS DE CARBONO Y EL ALQUILO INFERIOR CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO; Y R ELEVADO 3 ES HIDROGENO, HALOGENO, ALQUILO QUE CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO, ALCOXI INFERIOR QUE CONTIENE ENTRE 1 Y 6 ATOMOS DE CARBONO, TRIFLUOROMETILO, NITRO, ARILO O ARIL (ALQUILO INFERIOR) OXI DONDE EL ARILO CONTIENE ENTRE 6 Y 10 ATOMOS DE CARBONO Y EL ALQUILO INFERIOR CONTIENE ENTRE 1 Y 5 ATOMOS DE CARBONO, PROCESOS PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN. LOS COMPUESTOS TIENEN PROPIEDADES FARMACEUTICAS QUE LES HACEN BENEFICIOSOS PARA LA PREVENCION O TRATAMIENTO DE LAS COMPLICACIONES ASOCIADAS CON LA DIABETES MELITUS.
ES91304487T 1990-05-21 1991-05-17 Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa. Expired - Lifetime ES2110977T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/526,356 US5037831A (en) 1990-05-21 1990-05-21 Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
ES2110977T3 true ES2110977T3 (es) 1998-03-01

Family

ID=24097007

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304487T Expired - Lifetime ES2110977T3 (es) 1990-05-21 1991-05-17 Espiro-isoquinolein-pirrolidinas y analogos de las mismas, utiles como inhibidores de la aldosa-reductasa.

Country Status (11)

Country Link
US (1) US5037831A (es)
EP (1) EP0458551B1 (es)
JP (1) JP3244283B2 (es)
AT (1) ATE160780T1 (es)
CA (1) CA2042113C (es)
DE (1) DE69128302T2 (es)
DK (1) DK0458551T3 (es)
ES (1) ES2110977T3 (es)
GR (1) GR3026186T3 (es)
HK (1) HK1004067A1 (es)
SG (1) SG47773A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106978A (en) * 1991-05-22 1992-04-21 American Home Products Corporation Process and intermediates for the preparation of spiro(isoquinoline-4(1H), 3'-pyrrolidine)-1,2', 3,5'(2H)-tetrones which are useful as aldose reductase inhibitors
DK0618917T3 (da) * 1991-11-25 1997-10-13 American Home Prod 1Amino-2- (benzothiazolyl)methyl spiro isoquinolin-4(1h),3-pyrrolidin -1,2,3,5(2h)-tetroner og analoger deraf, der kan anvendes som aldosereduktaseinhibitorer.
US5189168A (en) * 1991-11-25 1993-02-23 American Home Products Corporation 1'-amino-2[(benzothiazolyl)methyl]spiro-[isoquinoline-4(1H),3'-pyrrolidine]-1,2'3,5'(2H)-tetrones and analogs thereof useful as aldose reductase inhibitors
US5189167A (en) * 1991-11-25 1993-02-23 American Home Products Corporation Alkylidene analogs of 1'-amino-2-[(benzothiazolyl)-methyl]spiro [isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrones useful as aldose reductase inhibitors
US5189044A (en) * 1992-03-20 1993-02-23 American Home Products Corporation Isoquinoline-1,3-dione acetyl carbamates useful as aldose reductase inhibitors
SK141899A3 (en) * 1997-04-15 2000-09-12 Csir Corporate Building Pharmaceutical compositions having appetite suppressant activity
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
EP2368560A1 (en) 2007-03-12 2011-09-28 Zadec ApS An anti-diabetic extract of rooibos
CA2685202C (en) 2007-03-23 2017-11-28 The Board Of Regents Of The University Of Texas System Methods for treating allergic asthma
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
AU2011348074B2 (en) 2010-12-23 2016-04-28 The Board Of Regents Of The University Of Texas System Methods for treating COPD
CN107286092B (zh) * 2017-05-24 2020-02-21 浙江大学 甲氧基苯甲酰胺和重氮酸酯经碳-氢官能化制备异喹啉二酮的方法
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
HU198051B (en) * 1984-10-30 1989-07-28 Pfizer Process for producing spiro square brackets open imidazolidine-4,5'(6h)-quinoline square brackets closed-2,5-dione derivatives
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
DE3769066D1 (de) * 1986-08-28 1991-05-08 Sanwa Kagaku Kenkyusho Co Hydantoin-derivate zur behandlung von komplikationen bei diabetes.
AU617541B2 (en) * 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors

Also Published As

Publication number Publication date
US5037831A (en) 1991-08-06
SG47773A1 (en) 1998-04-17
CA2042113C (en) 2001-08-28
DE69128302D1 (de) 1998-01-15
ATE160780T1 (de) 1997-12-15
EP0458551B1 (en) 1997-12-03
JPH04226984A (ja) 1992-08-17
HK1004067A1 (en) 1998-11-13
JP3244283B2 (ja) 2002-01-07
EP0458551A1 (en) 1991-11-27
DE69128302T2 (de) 1998-03-26
CA2042113A1 (en) 1991-11-22
DK0458551T3 (da) 1998-08-10
GR3026186T3 (en) 1998-05-29

Similar Documents

Publication Publication Date Title
SG47773A1 (en) Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
AU626740B2 (en) Aminocarbonylcarbamates related to physostigmine, a process for their preparation and their use as medicaments
DE68917772D1 (de) 2-Alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische Zusammensetzungen.
LV10235A (lv) Jauni esteri to iegusanas panemiens farmaceitiska kompozicija arstesanas metode
HUT50337A (en) Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds
RO92245A (ro) Procedeu pentru prepararea unor derivati de 1,6-naftiridina
CA2030732A1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE69016866D1 (de) Verwendung von Bis(4-hydroxyphenylthio)methan-Derivaten zur Behandlung von Diabetes mellitus.
GR70356B (es)
DK0410343T3 (da) Anvendelse af bisphenolderivater til behandling af diabetes mellitus
DE3473269D1 (en) (bis(substituted methyl)-methyl)-isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them
HUT67539A (en) 1-amino-2-[(benzothiazolyl)-methyl]-spiro-[isoquinoline-4(1h),-3'-pyrrolidine]-1,2',3,5'(2h)-tetrones, analogs thereof, process for producing them and pharmaceutical compositions containing them
SE8701524D0 (sv) Nya sulfonamider och deras framstellningsforfarande
DE3063105D1 (en) Clavulanic acid derivatives, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 458551

Country of ref document: ES